Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Doxofylline: Efficacy and safety in complex treatment of COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008
Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD Source: International Congress 2014 – COPD markers Year: 2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014
Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients Source: International Congress 2014 – Predictors Year: 2014
Treatment of COPD: from pharmacological to instrumental therapies Source: Eur Respir Rev 2009; 19: 7-23 Year: 2010
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Validation of FEV1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014